Figure 3From: Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanerceptSerum COMP (S-COMP) at baseline and after 3 months in rheumatoid arthritis patients treated with etanercept (a) or infliximab (b), grouped according to whether they were ACR20 responders (i.e., met the American College of Rheumatology criteria for 20% improvement) or nonresponders. Serum COMP was lower than at baseline after 3 months in all groups (P < 0.05 or better). For details, see text and Table 1.Back to article page